Truqap (capivasertib) Letter of Medical Necessity
Truqap (capivasertib) is an oral AKT inhibitor given with fulvestrant for biomarker-selected HR-positive, HER2-negative metastatic breast cancer. Denials usually cite a missing biomarker report or undocumented endocrine progression. A Letter of Medical Necessity should attach both up front.
FDA-Approved Indications
- ● HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or PTEN alterations, in combination with fulvestrant, after progression on endocrine therapy
Why Truqap Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. PIK3CA, AKT1, or PTEN alteration report not attached
- 2. Prior endocrine therapy progression not documented
- 3. Fulvestrant combination not specified
- 4. Baseline fasting glucose and HbA1c not documented
- 5. Preferred agent required first (e.g., alpelisib or elacestrant, by plan)
What to Include in a Truqap Letter of Medical Necessity
Attach the PIK3CA, AKT1, or PTEN alteration report, document prior endocrine therapy (including CDK4/6 inhibitor use) with progression dates, and specify combination with fulvestrant. Include baseline fasting glucose and HbA1c, and cite CAPItello-291 and the NCCN category for the line of therapy.
Key clinical evidence to cite:
- ✓ CAPItello-291 Phase 3 trial — longer progression-free survival with capivasertib plus fulvestrant vs fulvestrant alone in the AKT pathway-altered population
- ✓ FDA-approved companion diagnostic (FoundationOne CDx) for biomarker selection
- ✓ Intermittent dosing (4 days on, 3 days off) with a manageable hyperglycemia profile
Relevant guidelines:
- 📖 NCCN Breast Cancer Guidelines
- 📖 ASCO 2023 Endocrine Treatment and Targeted Therapy for HR+/HER2- Metastatic Breast Cancer Update
Truqap Prior Authorization Criteria
Standard criteria across major US payers for Truqap. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Prior endocrine therapy progression not documented
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Truqap
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Truqap Prior Authorization FAQ
Why was my Truqap prior authorization denied?
The most common denial reasons for Truqap are: PIK3CA, AKT1, or PTEN alteration report not attached; Prior endocrine therapy progression not documented; Fulvestrant combination not specified; Baseline fasting glucose and HbA1c not documented; Preferred agent required first (e.g., alpelisib or elacestrant, by plan).
What should a Truqap Letter of Medical Necessity include?
Attach the PIK3CA, AKT1, or PTEN alteration report, document prior endocrine therapy (including CDK4/6 inhibitor use) with progression dates, and specify combination with fulvestrant. Include baseline fasting glucose and HbA1c, and cite CAPItello-291 and the NCCN category for the line of therapy.
Which payers cover Truqap?
Truqap is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Humana, Medicare Part D, though formulary tier and prior authorization criteria vary.